Finding the sweet spot: the role of nature and nurture in medicinal chemistry

被引:303
作者
Hann, Michael M. [2 ]
Keserue, Gyoergy M. [1 ]
机构
[1] Gedeon Richter, Dept Discovery Chem, H-1103 Budapest, Hungary
[2] GlaxoSmithKline Med Res Ctr, Dept Computat & Struct Chem, Stevenage SG6 3LB, Herts, England
关键词
DRUG DISCOVERY; LEAD DISCOVERY; DEVELOPMENT PRODUCTIVITY; MOLECULAR COMPLEXITY; LIGAND EFFICIENCY; PROPERTY PROFILES; THERMODYNAMICS; LIPOPHILICITY; BINDING; IMPACT;
D O I
10.1038/nrd3701
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Given its position at the heart of small-molecule drug discovery, medicinal chemistry has an important role in tackling the well-known productivity challenges in pharmaceutical research and development. In recent years, extensive analyses of successful and failed discovery compounds and drug candidates have improved our understanding of the role of physicochemical properties in drug attrition. Based on the clarified challenges in finding the 'sweet spot' in medicinal chemistry programmes, we suggest that this goal can be achieved through a combination of first identifying chemical starting points with appropriate 'nature' and then rigorously 'nurturing' them during lead optimization. Here, we discuss scientific, strategic, organizational and cultural considerations for medicinal chemistry practices, with the aim of promoting more effective use of what is already known, as well as a wider appreciation of the risks of pursuing suboptimal compounds.
引用
收藏
页码:355 / 365
页数:11
相关论文
共 74 条
[1]   Ligand efficiency indices as guideposts for drug discovery [J].
Abad-Zapatero, C ;
Metz, JT .
DRUG DISCOVERY TODAY, 2005, 10 (07) :464-469
[2]   Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space [J].
Alex, Alexander ;
Millan, David S. ;
Perez, Manuel ;
Wakenhut, Florian ;
Whitlock, Gavin A. .
MEDCHEMCOMM, 2011, 2 (07) :669-674
[3]   Drug discovery in the next decade: innovation needed ASAP [J].
Bennani, Youssef L. .
DRUG DISCOVERY TODAY, 2011, 16 (17-18) :779-792
[4]  
Bickerton GR, 2012, NAT CHEM, V4, P90, DOI [10.1038/NCHEM.1243, 10.1038/nchem.1243]
[5]   Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates [J].
Braggio, Simone ;
Montanari, Dino ;
Rossi, Tino ;
Ratti, Emiliangelo .
EXPERT OPINION ON DRUG DISCOVERY, 2010, 5 (07) :609-618
[6]   Congeneric but Still Distinct: How Closely Related Trypsin Ligands Exhibit Different Thermodynamic and Structural Properties [J].
Brandt, Tobias ;
Holzmann, Nicole ;
Muley, Laveena ;
Khayat, Maan ;
Wegscheid-Gerlach, Christof ;
Baum, Bernhard ;
Heine, Andreas ;
Hangauer, David ;
Klebe, Gerhard .
JOURNAL OF MOLECULAR BIOLOGY, 2011, 405 (05) :1170-1187
[7]   The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development [J].
Butler, James M. ;
Dressman, Jennifer B. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (12) :4940-4954
[8]   Factors Determining the Selection of Organic Reactions by Medicinal Chemists and the Use of These Reactions in Arrays (Small Focused Libraries) [J].
Cooper, Tony W. J. ;
Campbell, Ian B. ;
Macdonald, Simon J. F. .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2010, 49 (44) :8082-8091
[9]   Opinion - Drug-target residence time and its implications for lead optimization [J].
Copeland, Robert A. ;
Pompliano, David L. ;
Meek, Thomas D. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :730-739
[10]  
Dack K., 2011, DESIGNING SAFER MED